Angelini Ventures, the corporate venture capital arm of Angelini Industries, focused on investing in early-stage companies in BioTech and Digital Health, co-leads €20m Series A funding round in Neumirna Therapeutics, accelerating next-generation RNA therapeutics for epilepsy and neurological diseases.
Angelini Ventures co-leads €20m Series A to advance RNA therapeutics for neurological disorders
Latest NewsAngelini Ventures, the corporate venture capital arm of Angelini Industries, focused on investing in early-stage companies in BioTech and Digital Health, co-leads €20m Series A funding round in Neumirna Therapeutics, accelerating next-generation RNA therapeutics for epilepsy and neurological diseases.
New RNA company Inverna Therapeutics launched
Latest NewsInverna Therapeutics, a Danish biotech company, has officially launched to develop innovative RNA-based therapies targeting severe genetic diseases. Co-founded by the University of Southern Denmark and Argobio, Inverna will focus on its lead programme addressing Huntington’s disease.
USD410m Mega Series A for yet another GLP-1 play?
Latest NewsVerdiva Bio, a London-based biotech, has raised an extraordinary US$410m in its oversubscribed Series A round, making it potentially the largest Series A ever raised by a U.K.-based biotech company, according to CEO Khurem Farooq.
Jeito Capital leads $67.5m Series B financing for cardiovascular gene therapy
Latest NewsA US$67.5m Series B financing in XyloCor Therapeutics led by French Jeito Capital will fund two double-blind Phase 2 trials for XC001, a pioneering gene therapy for severe cardiovascular disease.
Qiagen joins Newborn genomic screening of NHS
Latest NewsThe aim of this unique initiative, part of the so-called Generation Study, is to sequence the genomes of 100,000 newborns in England to enable the early detection of over 200 selected conditions and to accelerate the treatment of rare diseases.
WuXi Biologics Sells Irish Vaccine Site to Merck for $500m
Latest NewsWuXi Biologics has agreed to sell its Dundalk vaccine manufacturing facility to Merck, a move that will enhance asset efficiencies and allow the company to focus on CDMO services at its other global sites.
Orbis Medicines secures €90m to advance oral macrocycle drugs
Latest NewsOrbis Medicines secures €90m in Series A funding to accelerate the development of oral macrocycle drugs, leveraging automated chemistry and machine learning.
Merry Christmas and a Happy New Year
Latest NewsThank you for a successful 2024!
Sanofi expands collaboration with SK Bioscience
Latest NewsIn parallel with the expansion of its collaboration with SK Bioscience Co. Ltd, the French pharmaceutical company Sanofi SA has announced Phase III testing of its licensed pneumococcal conjugate vaccine PCV21.
New CEO completes management team
AppointmentsKufstein-based Single Use Support appointed Darren Verlenden as CEO and strengthens leadership team.